Bleeding and thrombosis in acute promyelocytic leukemia

Aditi Choudhry, Thomas G. Deloughery

Research output: Contribution to journalReview articlepeer-review

91 Scopus citations


Acute promyelocytic leukemia (APL) has evolved from being a deadly to a highly curable disease, due totargeted molecular therapy with all-trans retinoic acid (ATRA). As a result, the incidence of early hemorrhagic deaths for which APL is notorious has reduced to 5-10% as reported in clinical trials. These results are not replicated outside of clinical trials as is evident from recent population-based registries. High incidence of early hemorrhagic deaths remains the greatest contributor to treatment failure in this otherwise curable leukemia. Additionally, thrombosis is now being increasingly recognized in APL patients and may be associated with ATRA usage.

Original languageEnglish (US)
Pages (from-to)596-603
Number of pages8
JournalAmerican Journal of Hematology
Issue number6
StatePublished - Jun 2012

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Bleeding and thrombosis in acute promyelocytic leukemia'. Together they form a unique fingerprint.

Cite this